Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $49.30.

CLDX has been the subject of a number of research reports. The Goldman Sachs Group upped their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Monday, April 20th. Wells Fargo & Company upped their target price on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Finally, Wolfe Research raised shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price for the company in a report on Monday, March 23rd.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new position in shares of Celldex Therapeutics during the third quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Celldex Therapeutics during the third quarter worth about $42,000. Russell Investments Group Ltd. increased its stake in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the third quarter worth about $63,000. Finally, Kestra Advisory Services LLC acquired a new position in shares of Celldex Therapeutics during the fourth quarter worth about $98,000.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $29.35 on Friday. Celldex Therapeutics has a 1-year low of $19.52 and a 1-year high of $35.79. The stock has a market cap of $2.30 billion, a PE ratio of -6.89 and a beta of 0.95. The firm has a fifty day moving average price of $31.92 and a 200 day moving average price of $28.78.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, equities analysts expect that Celldex Therapeutics will post -4.36 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.